The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib
Open accessAbstract
OBJECTIVES: To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. METHODS: Double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score ≥301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D. RESULTS: The adjusted mean change (95% CI) in WOMAC pain was -185.7 (-200.3 to -171.1) (50.1% decrease) with CS+GH and -186.8 (-201.7 to -171.9) (50.2% decrease) with celecoxib, meeting the non-inferiority margin of -40: -1.11 (-22.0 to 19.8; p=0.92). All sensitivity analyses were consistent with that result. At 6 months, 79.7% of patients in the combination group and 79.2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups. CONCLUSIONS: CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile. TRIAL REGISTRATION NUMBER: NCT01425853.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Burden of major musculoskeletal conditions.
(2003) · Europe PMC (PubMed Central) · Cited by 3,521
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Jordan, K. M., Arden, N. K., Doherty, M., Bannwarth, B., Bijlsma, J. W. J., Dieppe, P., Gunther, K., Hauselmann, H., Herrero-Beaumont, G., Kaklamanis, P., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011742 · Cited by 2,048
Self-citationGastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
Wolfe, M. M., Lichtenstein, D. R., & Singh, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402407 · Cited by 1,956
THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
(1972) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-197254060-00035 · Cited by 1,647
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., Bradley, J. D., Bingham, C. O., Weisman, M. H., Jackson, C. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052771 · Cited by 1,329
Self-citationReginster, J. Y., Deroisy, R., Rovati, L. C., Lee, R. L., Lejeune, E., Bruyere, O., Giacovelli, G., Henrotin, Y., Dacre, J. E., & Gossett, C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03610-2 · Cited by 1,234
Self-citationReporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Cited by
Martel-Pelletier, J., Barr, A. J., Cicuttini, F. M., Conaghan, P. G., Cooper, C., Goldring, M. B., Goldring, S. R., Jones, G., Teichtahl, A. J., & Pelletier, J.-P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.72 · Cited by 1,877
Self-citationBruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., Al-Daghri, N. M., Herrero-Beaumont, G., Martel-Pelletier, J., Pelletier, J.-P., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.008 · Cited by 695
Self-citationArticular cartilage and osteochondral tissue engineering techniques: Recent advances and challenges
Wei, W., & Dai, H. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.011 · Cited by 327
Sulfation of Glycosaminoglycans and Its Implications in Human Health and Disorders
Soares da Costa, D., Reis, R. L., & Pashkuleva, I. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044610 · Cited by 324
Bruyère, O., Cooper, C., Pelletier, J.-P., Maheu, E., Rannou, F., Branco, J., Luisa Brandi, M., Kanis, J. A., Altman, R. D., Hochberg, M. C., et al. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.11.010 · Cited by 274
Self-citation
Metadata
- Authors
- Hochberg, M. C., Martel-Pelletier, J., Monfort, J., Möller, I., Castillo, J. R., Arden, N., Berenbaum, F., Blanco, F. J., Conaghan, P. G., Doménech, G., Henrotin, Y., Pap, T., Richette, P., Sawitzke, A., du Souich, P., & Pelletier, J.-P.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 75
- Issue
- 1
- Pages
- 37-44
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2156661254
- Cited by
- 281
- References
- 39
- FWCI
- 21.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. https://app.cochat.ai/papers/10.1136/annrheumdis-2014-206792
- The paper
- Hochberg, M. C., Martel-Pelletier, J., Monfort, J., Möller, I., Castillo, J. R., Arden, N., Berenbaum, F., Blanco, F. J., Conaghan, P. G., Doménech, G., Henrotin, Y., Pap, T., Richette, P., Sawitzke, A., du Souich, P., & Pelletier, J.-P. (2016). Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2014-206792
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.